Mild Cognitive Impairment - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Mild Cognitive Impairment - Pipeline Review, H1 2019’, provides an overview of the Mild Cognitive Impairment pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment

- The report reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Mild Cognitive Impairment therapeutics and enlists all their major and minor projects

- The report assesses Mild Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Addex Therapeutics Ltd

AgeneBio Inc

Avraham Pharmaceuticals Ltd

Biogen Inc

CereSpir Inc

CuraSen Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Fujifilm ...

AbbVie Inc

Addex Therapeutics Ltd

AgeneBio Inc

Avraham Pharmaceuticals Ltd

Biogen Inc

CereSpir Inc

CuraSen Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Fujifilm Toyama Chemical Co Ltd

Merck & Co Inc

Neuron Biopharma SA

Octapharma AG

Pfizer Inc

Protekt Therapeutics Ltd

Sage Therapeutics Inc

SBI Pharmaceuticals Co Ltd

Therapix Biosciences Ltd

Table of Contents

Table of Contents

Introduction

Mild Cognitive Impairment - Overview

Mild Cognitive Impairment - Therapeutics Development

Mild Cognitive Impairment - Therapeutics Assessment

Mild Cognitive Impairment - ...

Table of Contents

Introduction

Mild Cognitive Impairment - Overview

Mild Cognitive Impairment - Therapeutics Development

Mild Cognitive Impairment - Therapeutics Assessment

Mild Cognitive Impairment - Companies Involved in Therapeutics Development

Mild Cognitive Impairment - Drug Profiles

Mild Cognitive Impairment - Dormant Projects

Mild Cognitive Impairment - Discontinued Products

Mild Cognitive Impairment - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Mild Cognitive Impairment, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Tables

Number of Products under Development for Mild Cognitive Impairment, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Mild Cognitive Impairment - Pipeline by AbbVie Inc, H1 2019

Mild Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H1 2019

Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H1 2019

Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H1 2019

Mild Cognitive Impairment - Pipeline by Biogen Inc, H1 2019

Mild Cognitive Impairment - Pipeline by CereSpir Inc, H1 2019

Mild Cognitive Impairment - Pipeline by CuraSen Therapeutics Inc, H1 2019

Mild Cognitive Impairment - Pipeline by Eisai Co Ltd, H1 2019

Mild Cognitive Impairment - Pipeline by Eli Lilly and Co, H1 2019

Mild Cognitive Impairment - Pipeline by Fujifilm Toyama Chemical Co Ltd, H1 2019

Mild Cognitive Impairment - Pipeline by Merck & Co Inc, H1 2019

Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H1 2019

Mild Cognitive Impairment - Pipeline by Octapharma AG, H1 2019

Mild Cognitive Impairment - Pipeline by Pfizer Inc, H1 2019

Mild Cognitive Impairment - Pipeline by Protekt Therapeutics Ltd, H1 2019

Mild Cognitive Impairment - Pipeline by Sage Therapeutics Inc, H1 2019

Mild Cognitive Impairment - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2019

Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H1 2019

Mild Cognitive Impairment - Dormant Projects, H1 2019

Mild Cognitive Impairment - Dormant Projects, H1 2019 (Contd..1), H1 2019

Mild Cognitive Impairment - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Mild Cognitive Impairment, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Mild Cognitive Impairment, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports